Last €63.60 EUR
Change Today -0.373 / -0.58%
Volume 0.0
EWL On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 2:20 AM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One Edwards Way

Irvine, CA 92614

United States

Phone: 949-250-2500

Fax: 949-250-2525

Edwards Lifesciences Corporation focuses on technologies that treat structural heart disease and critically ill patients worldwide. The company manages its operations in the United States, Europe, Japan, and Rest of World. Product Offerings The products and technologies provided by the company are categorized into three primary areas, such as Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. Surgical Heart Valve Therapy This segment manufactures heart valves and repair products, which are used to replace or repair a patient's diseased or defective heart valve. The company produces pericardial valves from biologically inert animal tissue sewn onto proprietary wireform stents. The core of its surgical tissue heart valve product line is the Carpentier-Edwards PERIMOUNT pericardial valve, including the line of PERIMOUNT Magna Ease valves, the newest generation pericardial valves for aortic and mitral replacement. PERIMOUNT valves are the prescribed tissue heart valves in the world. In addition to its replacement valves, the company pioneered and provides heart valve repair therapies, including annuloplasty rings and systems. The company has also developed the EDWARDS INTUITY Valve System, a minimally invasive aortic heart valve system designed to enable a faster procedure, shorter patient time on cardiopulmonary bypass and a smaller incision. The company’s ThruPort systems enable minimal incision valve surgery where surgeons perform intricate procedures through small incisions, and allow surgeons to tailor procedures based on their preferred surgical approach. It also provides protection cannulae, which are used during cardiac surgery in venous drainage, aortic perfusion, venting, and cardioplegia delivery. Transcatheter Heart Valves The company has utilized the knowledge and experience from its Surgical Heart Valve portfolio to optimize transcatheter heart valve replacement technology, designed for the nonsurgical replacement of heart valves. The Edwards SAPIEN, Edwards SAPIEN XT, and Edwards SAPIEN 3 transcatheter aortic heart valves are used to treat heart valve disease using catheter-based approaches for certain patients deemed at risk for traditional open-heart surgery. The company offers its Transcatheter Heart Valves to patients commercially in Europe, the United States, and Japan. As of December 31, 2013, its transcatheter aortic heart valves were available for sale in approximately 60 countries. Critical Care The company provides hemodynamic monitoring systems used to measure a patient's heart function in surgical and intensive care settings. Hemodynamic monitoring enables a clinician to balance the oxygen supply and demand of a critically ill patient and plays a major role in ensuring tissue and organ perfusion, and patient outcomes and survival. The company’s hemodynamic monitoring technologies are used before, during, and after open-heart, major vascular, major abdominal, neurological, and orthopedic surgical procedures, as well as for acutely ill patients with conditions, such as sepsis, acute respiratory distress syndrome, and multi-organ failure. The company manufactures the FloTrac continuous cardiac output monitoring system, a minimally invasive cardiac monitoring technology for goal-directed hemodynamic optimization. Its hemodynamic monitoring product line also includes the Swan-Ganz line of pulmonary artery catheters, and the PreSep continuous venous oximetry catheter for measuring central venous oxygen saturation. Its VolumeView sensor-catheter set measures a critically ill patient's volumetric hemodynamic parameters, while the EV1000 clinical monitoring platform displays a patient's physiologic status and integrates majority of its sensors and catheters into one intuitive platform. The company extended its Critical Care product offering with the acquisition of a non-invasive hemodynamic monitoring product line. It intends to integrate this product, ClearSight, into its EV1000 clinical platform in 2014. The company also provides disposable pressure monitoring devices and closed blood sampling systems to help protect both patients and clinicians

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EWL:GR €63.60 EUR -0.373

EWL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $67.25 USD +0.07
Hologic Inc $25.51 USD +0.18
MEDNAX Inc $57.67 USD +0.16
Mettler-Toledo International Inc $252.84 USD -1.33
Cooper Cos Inc/The $149.54 USD +4.29
View Industry Companies
 

Industry Analysis

EWL

Industry Average

Valuation EWL Industry Range
Price/Earnings 31.5x
Price/Sales 4.5x
Price/Book 6.8x
Price/Cash Flow 29.8x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDWARDS LIFESCIENCES CORP, please visit www.edwards.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.